Galcanezumab
Red
Brand:
Nice TA:
659
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Central nervous system
Background
1.1 Galcanezumab is recommended as an option for preventing migraine in adults, only if:
• they have 4 or more migraine days a month
• at least 3 preventive drug treatments have failed and
• the company provides it according to the commercial arrangement.